CYP2C11 played a significant role in down-regulating rat blood pressure under the challenge of a high-salt diet

Wei Liu 1, Danjuan Sui 1, Huanying Ye 1, Zhen Ouyang 1, Yuan Wei Corresp. 1

1 School of Pharmacy, Jiangsu University, Zhenjiang, China
Corresponding Author: Yuan Wei
Email address: ywei@ujs.edu.cn

Background. Arachidonic acid (AA) is oxidized by cytochrome P450s (CYPs) to form epoxyeicosatrienoic acids (EETs), compounds that modulate ion transport, gene expression, and vasorelaxation. Both CYP2Cs and CYP2Js are involved in kidney EET epoxidation.

Methods. In this study, we used a CYP2C11-null rat model to explore the in vivo effects of CYP2C11 on vasorelaxation. For 2 months, CYP2C11-null and wild-type Sprague-Dawley rats were either fed normal lab (0.3% (w/w) sodium chloride) or high-salt (8% (w/w) sodium chloride) diets. Subsequently, an invasive method was used to determine blood pressure. Next, western blots, quantitative PCR, and immunohistochemistry were used to determine renal expression of CYPs involved in AA metabolism.

Results. Among CYP2C11-null rats, a high-salt diet (females: 156.79 ± 15.89 mm Hg, males: 130.25 ± 16.76 mm Hg, n = 10) resulted in significantly higher blood pressure than a normal diet (females: 118.05 ± 8.43 mm Hg, P < 0.01; males: 115.15 ± 11.45 mm Hg, P < 0.05, n = 10). Compared with wild-type rats under the high-salt diet, western blots showed that CYP2C11-null rats had higher renal expression of CYP2J2 and CYP4A. This was consistent with the results of immunohistochemistry and the qPCR, respectively. The two rat strains did not differ in the renal expression of CYP2C23 or CYP2C24.

Conclusion. our findings suggested that CYP2C11 plays an important role in lowering blood pressure under the challenge of a high-salt diet.
CYP2C11 Played a Significant Role in Down-regulating Rat Blood Pressure under the Challenge of a High-Salt Diet

Wei Liu, Danjuan Sui, Huanying Ye, Zhen Ouyang, and Yuan Wei*

School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu, China

Corresponding Author:
Yuan Wei
301 Xuefu Road, Zhenjiang, Jiangsu, 212013, China
Email address: ywei@ujs.edu.cn

Abstract

Background. Arachidonic acid (AA) is oxidized by cytochrome P450s (CYPs) to form epoxyeicosatrienoic acids (EETs), compounds that modulate ion transport, gene expression, and vasorelaxation. Both CYP2Cs and CYP2Js are involved in kidney EET epoxidation.

Methods. In this study, we used a CYP2C11-null rat model to explore the in vivo effects of CYP2C11 on vasorelaxation. For 2 months, CYP2C11-null and wild-type Sprague-Dawley rats were either fed normal lab (0.3% (w/w) sodium chloride) or high-salt (8% (w/w) sodium chloride) diets. Subsequently, an invasive method was used to determine blood pressure. Next, western blots, quantitative polymerase chain reaction (qPCR), and immunohistochemistry were used to determine renal expression of CYPs involved in AA metabolism.

Results. Among CYP2C11-null rats, a high-salt diet (males: 130.25 ± 16.76 mm Hg, females: 156.79 ± 15.89 mm Hg, n = 10) resulted in significantly higher blood pressure than a normal diet (males: 115.15 ± 11.45 mm Hg, P < 0.05, females: 118.05 ± 8.43 mm Hg, P < 0.01; n = 10). Compared with wild-type rats under the high-salt diet, western blots showed that CYP2C11-null rats had higher renal expression of CYP2J2 and CYP4A. This was consistent with the results of immunohistochemistry and the qPCR, respectively. The two rat strains did not differ in the renal expression of CYP2C23 or CYP2C24.

Conclusion. Our findings suggested that CYP2C11 plays an important role in lowering blood pressure under the challenge of high-salt diet.

Introduction

Hypertension is a common condition that can lead to ischemic heart disease, cerebrovascular disease, and chronic kidney disease (Collins et al. 2000; Van Gaal et al. 2006; Wright 2006). Therefore, regulating blood pressure is an effective way to reduce heart attack and heart failure incidence (Ambrosius et al. 2014; Peng et al. 2017; Zanchetti et al. 2015). Arachidonic acid (AA) is an omega-6 fatty acid with substantial effects on blood pressure in rats and humans. The kidneys primarily produce the following AA metabolites: regional and stereoisomeric...
epoxycosatrienoic acids (EETs) (Holla et al. 1999; Makita et al. 1996; Marji et al. 2002; Yu et al. 2000), as well as 20-hydroxyicosatetraenoic acids (20-HETEs) (Imig 2005; Marji et al. 2002; Zhao et al. 2003). AA CYP-epoxidase metabolites inhibit epithelial sodium channel activity in the cortical collecting duct (Capdevila et al. 2014; Jorge & Wenhui 2013), where 11,12-EET is primarily responsible for mediating the inhibition of epithelial Na channels. 11,12-EET also stimulates the Ca\(^{2+}\)-activated large conductance potassium channel and afferent arteriolar smooth muscle in the cortical collecting duct (Jorge & Wenhui 2013).

In the kidneys, CYP4As (a type of cytochrome P450) catalyzes the formation of 20-HETE (Makita et al. 1996; Marji et al. 2002), which regulates vascular tone and electrolyte excretion (Imig 2005). Through contracting peripheral blood vessels, 20-HETE promotes hypertension, but also inhibits Na and water absorption to exert anti-hypertensive effects (Marji et al. 2002). In rat kidneys, CYP2Cs and CYP2Js are the main producers of EETs (Zhao et al. 2003). The latter promotes microvascular dilation (Imig et al. 1996; Zhao et al. 2003), profibrinolytic effects, anti-inflammation, and inhibition of smooth muscle cell migration (Campbell 2000; Fleming 2001; Holla et al. 1999; Node et al. 2001). Among the cytochrome P450s, CYP2C11 epoxidizes AA to 11,12-EET and 14,15-EET with nearly equal efficiency, CYP2J mainly produces 14,15-EET, while CYP2C23 mainly epoxidizes AA to 11,12-EET, (Holla et al. 1999; Marji et al. 2002; Roman 2002; Wójcikowski & Daniel 2009; Yu et al. 2000). The latter is strongly influential in expanding blood vessels (Krötz et al. 2004; Node et al. 2001), suggesting that kidney CYP2Cs are important to controlling hypertension. The most highly expressed CYP2C in rat kidneys is CYP2C23, whereas CYP2C11 expression is much lower (Zhao et al. 2003). However, a portion of CYP2C23 is actually present in an inactivated form (Kaergel et al. 2002). Thus, the specific roles of CYP2Cs in EET-mediated blood-pressure regulation remain unclear.

Using a \textit{CYP2C11}-null rat model that we had previously generated (Wei et al. 2018), here we examined how CYP2C11 influences EET function \textit{in vivo}. We challenged \textit{CYP2C11}-null and wild-type (WT) Sprague-Daly (S-D) rats with a high-salt diet to understand how blood pressure would change in response. We also investigated the expression of other P450s involved in renal AA metabolism, including CYP2C23, CYP2C24, CYP2J, and CYP4A.

\textbf{Materials & Methods}

\textbf{Chemicals and Reagents}

Normal (0.3\% (w/w) sodium chloride) and high-salt (8\% (w/w) sodium chloride) rat grains were purchased from Xietong Organism (Nanjing, China). PageRuler\textsuperscript{TM} Prestained Protein Ladder and RevertAid First Strand cDNA Synthesis Kit were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Immobilon\textsuperscript{TM} Western Chemiluminescent horseradish peroxidase (HRP) Substrate (ECL) was purchased from the EMD-Millipore (Billerica, MA, USA). CYP2J2 Rabbit Polyclonal antibody (Catalog number: 13562-1-AP) was purchased from Proteintech Group (Rosemont, IL, USA). The anti-CYP4A rabbit polyclonal antibody (catalog number: ab3573) was purchased from Abcam (Cambridge, UK). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer, enhanced bicinchoninic
acid protein assay kit, and HRP-labelled goat anti-rabbit IgG (H+L) (Catalog number: A0208) were purchased from Beyotime (Jiangsu, China). The HRP-polymer anti-mouse/rabbit antibody (catalog number: KIT-5030) and 3,3′-diaminobenzidine substrate were purchased from Maixin Biotech (Fuzhou, China). The UltraSYBR Mixture was purchased from ComWin Biotech (Beijing, China). DNase/RNase-free water was purchased from Solarbio Science & Technology (Beijing, China). Sodium phenobarbital (> 98.5% purity) and all other reagents were purchased from Sinopharm Chemical Reagent (Shanghai, China).

Animals

The CYP2C11-null (knockout) rat model was generated using the CRISPR/Cas9 method to insert a 2 bp GT fragment into exon 6 of CYP2C11 (Wei et al. 2018). Rats were cultured at the Laboratory Animal Center of Jiangsu University (SPF grade). WT S-D rats (male and female, mean body weight 220 ± 10 g) were purchased from the Laboratory Animal Center of Jiangsu University (permit number SKXX [Su] 2013-0011). The breeding room environment was 22–25°C with a relative humidity of 65% and a 12-h light/dark cycle. All subjects were allowed ad libitum access to water. Animal reproduction and experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of Jiangsu University.

Animal experiments for measuring blood pressure

For the control (normal diet) condition, two-month-old rats weighing 220 ± 10 g were divided into four groups, each containing 10 rats. Both sexes and strains (WT and CYP2C11-null) were represented equally. The same grouping method was used for the high-salt condition (Matrougui et al. 1998). Feeding duration was two months.

Blood pressure was measured using a classic invasive method (Schenk et al. 1992) with modifications. First, 150 mg/kg sodium phenobarbital was administered through an intraperitoneal injection. After disinfection, a small incision was made in the neck to reach the carotid artery. The artery’s upper part (near the brain) was tightened with a surgical line before inserting a thin tube with a three-way valve filled with heparin sodium solution (25 U/mL). The other end of the three-way valve was connected to a bio-signal collector. Blood pressure signals were collected using Chart version 5.0.1 (ADInstruments NSW, Australia).

Western blots with rat kidney microsomes

Rats were euthanized with carbon dioxide after measuring their blood pressure. Renal microsomes were obtained with differential centrifugation (Ding & Coon 1990). In brief, 0.5 g of kidney tissue were obtained and rinsed with ice-cold 0.9% sodium chloride solution. The tissue was then homogenized with 6 mL of KCl-sucrose buffer for 3 × 15 seconds and centrifuged at 9000 × g for 20 minutes at 4°C. The resultant supernatant was then centrifuged at 100 000 × g for 1 hour at 4°C. The resulting microsomal pellet was ground to a particle-free state after adding 1 mL of glycerol-phosphate buffer to a glass homogenizer and stored at -80 °C for use. The microsomal protein concentration was determined using a bicinchoninic acid kit (Beyotime). Proteins (5 µg) (J et al. 2003) were then subjected to 10% SDS-PAGE with duplicate adjacent lanes, and transferred to an Immobilon-P Transfer Membrane (EMD-Millipore). Duplicate SDS-
PAGE was performed and Ponceau S was used to ensure that sample proteins were loaded equally (Wang et al. 2017). The common reference proteins, β-actin and GAPDH, were not used because they are absent from renal microsomes. Membranes were blocked in 5% skim milk (Murraygoulburn Cooperative, Brunswick, VIC, Australia), probed with primary antibodies (1:1000), and then incubated with species-specific HRP-conjugated secondary antibodies (Beyotime, 1:1000). Signals were detected using an ECL system (Clinx Science Instruments, Shanghai, China). The western blotting analysis was repeated three times and images were analyzed with Image J software (version 1.46, National Institutes of Health, Bethesda, MD, USA).

**Quantitative polymerase chain reaction (qPCR) analysis**

Because CYP2C23 and CYP2C24 antibodies were unavailable, renal mRNAs were analyzed to determine expression of these CYPs. Renal mRNA levels of CYP2J2 and CYP4A1 were also analyzed. Total RNA was isolated using a TRIzol reagent (ComWin Biotech, Beijing, China) following the manufacturer’s protocol. Complementary DNA was synthesized from 5 μg of RNA using a cDNA Synthesis Kit (Thermo Fisher Scientific) and eluted in a final volume of 20 μL.

qPCR was performed using the LightCycler96 Real-time PCR system (Roche, Basel, Switzerland). Primers (*Table 1*) for CYP2C23, CYP2C24, and β-actin were synthesized by Sangon Biotech (Shanghai, China). The thermocycling profile was 95°C for 600 s, followed by 46 cycles of 95°C for 15 s, 61°C for 20 s, and 72°C for 30 s. The $2^{-ΔΔCt}$ method was used to calculate the relative changes in target gene expression from the qPCR results, using β-actin as the reference gene.

### Immunohistochemistry

Fixed kidney sections were de-waxed and rehydrated following published methods (Becker et al. 2006). Endogenous peroxidase was inactivated through 0.3% hydrogen peroxide treatment for 10 min. Treatment with phosphate-buffered saline for 5 min blocked non-specific binding. Sections were then incubated with primary antibodies (CYP2J2, 1:100; CYP4A1, 1:300) overnight at 4°C, followed by the secondary antibody (Maixin, 1:20) for 20 min. Sections were stained for 2 min with 3,3′-diaminobenzidine substrate, then rinsed with distilled water before being dehydrated and covered in a neutral resin/xylene mixture. Section images were obtained under 200× magnification in five randomly selected microscopic fields and analyzed in Image-Pro Plus version 6.0 (Media Cybernetics, Rockville, MD, USA). The integral optical density (IOD) and total area of the positive reaction region in each field of vision were automatically generated by the software. Their ratio was the mean density (IOD/area).

### Statistical analysis

All data are expressed as means ± standard deviation. Student’s *t*-test was used to determine differences in means. Analyses were performed in Prism 6.0 (GraphPad, La Jolla, CA, USA), and P < 0.05 was considered statistically significant.
Results

High-salt diets elevated blood pressure in CYP2C11-null rats

Under a normal lab diet, CYP2C11-null and WT rats did not differ in blood pressure (n = 10). Among CYP2C11-null rats, male and female average blood pressure was 115.2 ± 11.5 mm Hg and 118.1 ± 8.4 mm Hg, respectively. Among WT, male and female blood pressure was 120.4 ± 11.4 mm Hg and 120.0 ± 16.5 mm Hg. However, a high-salt diet significantly increased blood pressure (male: 130.3 ± 16.8 mm Hg, female: 156.8 ± 15.9 mm Hg; n = 10) among CYP2C11-null rats compared with a normal diet (male: 115.2 ± 11.5 mm Hg, P < 0.05, female: 118.1 ± 8.4 mm Hg, P < 0.01; n = 10). The increase in CYP2C11-null females was significantly higher than in CYP2C11-null males and WT females (128.5 ± 21.8 mm Hg, n = 10, P < 0.01) (Fig. 1).

Western blots of CYP2J2 and CYP4A in rat kidney microsomes

Under the normal diet, the expression of CYP2J2 in CYP2C11-null male rats was significantly higher than that in WT male rats. In addition, the expression of CYP4A in CYP2C11-null female rats was significantly lower than that in WT female rats (P < 0.01). The high-salt diet significantly increased renal CYP2J2 and CYP4A expression in both male and female CYP2C11-null rats compared with WT rats (P < 0.01). (Fig. 2)

Renal mRNA expression

After knocking out the CYP2C11 gene, renal CYP2C23 and CYP2C24 mRNA did not differ between CYP2C11-null and WT rats of either sex (n = 9). The results showed that the high-salt diet treatment had no effects on renal CYP2C23 or CYP2C24 mRNA expression. The mRNA levels of these genes in the two rat strains under the normal diet were consistent with the results of western blotting. Under the high-salt diet, renal expression of CYP2J2 and CYP4A1 mRNA in CYP2C11-null male rats was significantly higher than that in WT male rats (P < 0.01, n = 9) (Fig. 3).

Immunohistochemistry

Positive staining for CYP2J2 was observed in the renal cortex and outer medulla of all groups. The positive reaction of CYP2C11-null female rats treated with the normal diet was enhanced compared to WT female rats. The positive reaction and staining intensity of the CYP2C11-null rats treated with a high-salt diet were increased compared to WT rats. Renal sections of all groups were observed to be positively stained for CYP4A in interlobar, arcuate, and interlobular arteries. However, no positive enhancement was observed in the sections (Fig. 4 Part A). Under a normal diet, renal CYP2J2 expression was significantly elevated in CYP2C11-null females compared with WT females (P < 0.01, n = 5). We observed the same between-strain difference under the high-salt diet, except in both sexes (P < 0.01, n = 5). No significant difference was found for CYP4A expression (Fig. 4 Part B).
Discussion

In this study, we provided the first in vivo evidence of CYP2C11 function in EET-mediated blood pressure regulation. Our results showed that high-salt diets only elevated blood pressure in CYP2C11 knockout rats, but did not affect blood pressure in WT S-D rats. Thus, high sodium alone was insufficient for blood-pressure increases, consistent with previous reports (Zhao et al. 2003), and rats without CYP2C11 were more vulnerable to the challenge of the high-salt diet.

In the kidney, CYPs generate two major classes of AA metabolites: HETEs (20- and 19-HETE) (Fleming 2001) and EETs (5,6-, 8,9-, 11,12-, and 14,15-EET) (Capdevila & Falck 2000; Capdevila et al. 1992; Makita et al. 1996; Wu et al. 1997). In particular, CYP4A generates 20-HETE, a ω-hydroxylation product of AA that is important to blood pressure regulation (Müller et al. 1996; Roman 2002). Previous research has provided clear evidence of CYP4A involvement in 20-HETE production (Escalante et al. 2002; Oyekan et al. 1999; Wang et al. 2003), as the inhibition of nitric oxide synthase restored elevated blood pressure. Removing nitric oxide increases ω-hydroxylase activity (Wang et al. 2003), CYP4A protein expression (Oyekan et al. 1999), and 20-HETE production in the kidney (Oyekan et al. 1999; Wang et al. 2003). In the present study, western blots showed that the high-salt diet significantly elevated renal CYP2J2 and CYP4A expression, but immunohistochemistry only revealed a significant between-group difference in renal CYP2J2 expression under the high-salt diet. Because the high-salt diet significantly elevated renal CYP4A mRNA expression, the salt-induced elevation in blood pressure might be slightly compensated by the formation of 20-HETE.

We also demonstrated that CYP2C11 metabolites had important physiological functions. Although equipment and technical limitations prevented us from monitoring EETs and 20-HETEs, we found that CYP2C11 metabolites had important physiological functions in the regulation of blood pressure in rats. EETs are known contributors to kidney function through their direct effects on tubular transport processes, vascular tone, and cellular proliferation (Fisslthaler et al. 2000; Imig et al. 1996). The ratio of vasodilating (primarily 11,12- and 14,15-EET) to vasoconstrictive EETs (primarily 5,6-EET) controlled which process occurred (Yu et al. 2000). Of these EETs, 5,6 metabolites are extremely unstable, causing difficulties for measuring 5,6-EET formation in vitro and in vivo (Yu et al. 2000). In rat renal microsomes, only a negligible amount of 5,6-EET was found due to low production from CYP2C11, CYP2C23, CYP2C24, and CYP2J (Capdevila et al. 1992; Holla et al. 1999; Karara et al. 1993; Wu et al. 1997). The 8,9-, 11,12-, and 14,15-EETs were considered to have important physiological functions. CYP2C11 catalyzed the oxidation of 11, 12- and 14, 15-EETs with almost the equal efficiency (Holla et al. 1999). However, the highly expressed CYP2C23 catalyzed the formation of 8,9-, 11,12- and 14,15-EET at a ratio of approximately 1:2:1 in the rat kidney (Karara et al. 1993). Furthermore, CYP2J isoforms preferentially catalyzed AA to 14,15-EET (Zhao et al. 2003).

In our study, CYP2C11 knockout did not affect renal CYP2C23 and CYP2C24 mRNA expression. Thus, these two proteins are highly unlikely to be involved in the processes that elevate blood pressure after a high-salt diet. Similarly, research comparing spontaneously
hypertensive rats to WKY rats shows that CYP2C11, CYP2C23, and CYP2C24 are expressed at
similar levels in the renal cortex (Yu et al. 2000). Furthermore, a high-salt diet induced CYP2J
expression in CYP2C11-null rats but not in WT rats, consistent with the finding that CYP2J is
elevated in spontaneously hypertensive rats (Yu et al. 2000). Therefore, inducing CYP2J2
expression in CYP2C11 knockout rats caused a slight compensatory effect that was nevertheless
insufficient to fully replace CYP2C11.

Rat CYP2C11 is expressed specifically in males and barely present in females. Thus,
knockout of CYP2C11 might cause greater compensatory effects from other P450s in males. We
speculate that, under the challenge of a high-salt diet, the compensatory effects in CYP2C11-null
females were exhausted, resulting in a more significant increase in blood pressure compared to
that in CYP2C11-null males. Compared with WT females, CYP2C11-null females also had a
more significant increase in blood pressure under the high-salt diet. This could be explained by
the function of CYP2C11 in WT females, despite its very low expression level.

Conclusions
CYP2C11 plays a key role in mitigating the elevated blood pressure resulting from a high-
salt diet. We confirmed that in vivo CYP function is associated with sodium-induced
hypertension. Although more research is necessary to confirm the relevance of CYP to sodium-
induced hypertension in humans, our results corroborate human research showing that CYP2J2
(Wu et al. 2012) and CYP4A11(Z et al. 2008) are related to hypertension. Additionally, our
CYP2C11-null rat model should benefit further study on this topic.

Acknowledgements
We would like to thank Professor Miao Chen of the Department of Pathology, First People’s
Hospital, Zhenjiang, China, for immunohistochemistry analysis of rat tissue samples.

References
Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Jr GD,
Johnson KC, and Killeen AA. 2014. The design and rationale of a multicenter clinical trial
comparing two strategies for control of systolic blood pressure: the Systolic Blood
Pressure Intervention Trial (SPRINT). Clinical Trials 11:532.
Becker A, Albrecht C, Knaapen AM, Schins RPF, Höhr D, Ledermann K, and Borm PJA. 2006.
Induction of CYP1A1 in rat lung cells following in vivo and in vitro exposure to quartz.
Archives of Toxicology 80:258-268.
Campbell WB. 2000. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators.
Trends in Pharmacological Sciences 21:125-127.
Capdevila J, and Falck J, Rc. 2000. Cytochrome P450 and arachidonic acid bioactivation.
Molecular and functional properties of the arachidonate monooxygenase. Journal of
Lipid Research 41:163-181.
Capdevila JH, Nataliya P, Shaojun M, Yan G, Falck JR, Imig JD, Harris RC, and Wenhui W.
2014. The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the
blood pressure responses to increased dietary salt. Journal of Biological Chemistry
289:4377-4386.
Capdevila JH, Wei S, Yan J, Karara A, Jacobson HR, Falck JR, Guengerich FP, and Dubois RN. 1992. Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. *Journal of Biological Chemistry* 267:21720.

Collins R, Peto R, Macmahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, and Hennekens CH. 2000. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet* 335:827-838.

Ding XX, and Coon MJ. 1990. Immunochemical characterization of multiple forms of cytochrome P-450 in rabbit nasal microsomes and evidence for tissue-specific expression of P-450s NMa and NMb. *Molecular Pharmacology* 37:489.

Escalante BA, Mcgiff JC, and Oyekan AO. 2002. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. *American Journal of Physiology Renal Physiology* 282:F144.

Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. 2000. Cytochrome P450 2C is an EDHF synthase in coronary arteries. *Trends in Cardiovascular Medicine* 10:166-170.

Fleming I. 2001. Cytochrome p450 and vascular homeostasis. *Circulation Research* 89:753.

Holla VR, Makita K, Zaphiropoulos PG, and Capdevila JH. 1999. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. *Journal of Clinical Investigation* 104:751.

Imig JD. 2005. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. *American Journal of Physiology Renal Physiology* 289:F496-F503.

Imig JD, Navar LG, Roman RJ, Reddy KK, and Falck JR. 1996. Actions of epoxygenase metabolites on the preglomerular vasculature. *Journal of the American Society of Nephrology* 7:2364-2370.

J G, Y W, QY Z, H C, M B, L W, W Y, L Z, and X D. 2003. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. *Journal of Biological Chemistry* 278:25895-25901.

Jorge C, and Wenhui W. 2013. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. *Curr Opin Nephrol Hypertens* 22:163-169.

Kaergel E, Muller DN, Honeck H, Theuer J, Shagdarsuren E, Mullally A, Luft FC, and Schunck WH. 2002. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. *Hypertension* 40:273-279.

Karara A, Makita K, Jacobson HR, Falck JR, Guengerich FP, Dubois RN, and Capdevila JH. 1993. Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenase. *Journal of Biological Chemistry* 268:13565-13570.

Krötz F, Riezinger T, Buerkle MA, Nithipatikom K, Gloc T, Sohn HY, Campbell WB, and Pohl U. 2004. Membrane Potential-Dependent Inhibition of Platelet Adhesion to Endothelial Cells by Epoxycisatrienoic Acids. *Arterioscler Thromb Vasc Biol* 24:595-600.

Müller CM, Scierka A, Stiller RL, Kim YM, Cook DR, Jr LJ, Buffington CW, and Watkins WD. 1996. Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. *Anesthesiology* 84:1435-1442.

Makita K, Falck JR, and Capdevila JH. 1996. Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. *Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology* 10:1456-1463.

Marji JS, Wang MH, and Laniadoschwartzman M. 2002. Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries. *American Journal of Physiology Renal Physiology* 283:F60.
Matrougui K, Schiavi P, Guez D, and Henrion D. 1998. High Sodium Intake Decreases Pressure-Induced (Myogenic) Tone and Flow-Induced Dilation in Resistance Arteries From Hypertensive Rats. *Hypertension* 32:176-179.

Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, and Liao JK. 2001. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. *Journal of Biological Chemistry* 276:15983-15989.

Oyekan AO, Youseff T, Fulton D, Quilley J, and Mcgiff JC. 1999. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. *Journal of Clinical Investigation* 104:1131-1137.

Peng W, Lauche R, Ferguson C, Frawley J, Adams J, and Sibbritt D. 2017. Efficacy of Chinese herbal medicine for stroke modifiable risk factors: a systematic review. *Chinese Medicine* 12:25.

Roman RJ. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. *Physiological Reviews* 82:131.

Schenk J, Hebden A, and Mcneill JH. 1992. Measurement of cardiac left ventricular pressure in conscious rats using a fluid-filled catheter. *Journal of Pharmacological & Toxicological Methods* 27:171-175.

Van Gaal LF, Mertens IL, and De Block CE. 2006. Mechanisms linking obesity with cardiovascular disease. *Nature* 444:875-880.

Wójcikowski J, and Daniel WA. 2009. The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. *Expert Opin Drug Metab Toxicol* 5:631-645.

Wang DJ, Wang K, Sui DJ, Ouyang Z, Xu HY, and Wei Y. 2017. Effects of tetrahydroberberine and tetrahydropalmatine on hepatic cytochrome P450 expression and their toxicity in mice. *Chemico-Biological Interactions* 268:47-52. 10.1016/j.cbi.2017.02.019

Wang MH, Wang J, Chang HH, Zand BA, Jiang M, Nasjletti A, and Lania doschwartzman M. 2003. Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. *Am J Physiol Renal Physiol* 285:F295.

Wei Y, Yang L, Zhang X, Sui D, Wang C, Wang K, Shan M, Guo D, and Wang H. 2018. Generation and Characterization of a CYP2C11-null Rat Model by using the CRISPR/Cas9 method. *Drug Metabolism & Disposition* 46:525-531.

Wright JT. 2006. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial (vol 288, pg 2421, 2002). *Jama the Journal of the American Medical Association* 295:2726-2726.

Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, and Zeldin DC. 1997. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. *Journal of Biological Chemistry* 272:12551-12559.

Wu SN, Zhang Y, Gardner CO, Chen Q, Li Y, Wang GL, Gao PJ, and Zhu DL. 2012. Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. *Annals of Human Genetics* 71:519-525.

Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, and Kroetz DL. 2000. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. *Molecular Pharmacology* 57:1011-1020.

Z F, T N, N S, Y I, Y K, A S, M O, M S, N A, and M S. 2008. A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men. *Journal of Hypertension* 26:453-461.

Zanchetti A, Thomopoulos C, and Parati G. 2015. Randomized Controlled Trials of Blood Pressure Lowering in Hypertension: A Critical Reappraisal. *Circulation Research* 116:1058-1073.
Zhao X, Pollock DM, Inscho EW, Zeldin DC, and Imig JD. 2003. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. *Hypertension* 41:709-714.
Figure 1

High-salt diets elevated blood pressure in CYP2C11-null rats.

A high-salt diet significantly increased blood pressure among CYP2C11-null rats compared with a normal diet (female, P < 0.01, male, P < 0.05; n = 10). The increase in CYP2C11-null females was significantly higher than in CYP2C11-null males and WT females (P < 0.01, n = 10). All data are expressed as mean ± standard deviation. *P < 0.05, **P < 0.01.
Figure 2

Western blots of CYP2J2 and CYP4A in rat kidney microsomes.

Representative western blots showing 57-kDa CYP2J2 and 50-kDa CYP4A protein bands in CYP2C11-null rats and WT rats in the normal and high-salt diet. Proteins were loaded in duplicate adjacent lanes. Under the normal diet, the expression of CYP2J2 in CYP2C11-null male rats was significantly higher than that in WT male rats. In addition, the expression of CYP4A in CYP2C11-null female rats was significantly lower than that in WT female rats (P < 0.01). The high-salt diet significantly increased renal CYP2J2 and CYP4A expression in both male and female CYP2C11-null rats compared with WT ones. Integrated density of the WT rats was regarded as 100%. All data were expressed as means ± standard deviation. **P < 0.01.
Figure 3

Quantitative PCR of renal mRNA expression.

After knocking out the CYP2C11 gene, renal CYP2C23 and CYP2C24 mRNA did not differ between CYP2C11-null and WT rats of either sex (n = 9). The results showed that the high-salt diet treatment had no effects on renal CYP2C23 or CYP2C24 mRNA expression. Under the normal diet, the mRNA expression of CYP2J2 in CYP2C11-null male rats was significantly higher than that in WT male rats (P < 0.01, n = 9), and the mRNA expression of CYP4A1 in CYP2C11-null female rats was significantly lower than that in WT female rats (P < 0.01, n = 9). Under the high-salt diet, renal expression of CYP2J2 and CYP4A1 mRNA in CYP2C11-null male rats was significantly higher than that in WT male rats (P < 0.01, n = 9). All data were expressed as means ± standard deviation. *P < 0.05, **P < 0.01.
Figure 4

Immunohistochemistry (cytoplasmic, positive) of CYP2J2 and CYP4A (magnification, × 200).

(A): Positive staining for CYP2J2 was observed in the renal cortex and outer medulla of all groups. Under the normal diet, the positive reaction of D group was enhanced compared to B group. Under the high-salt diet, the positive reaction and staining intensity of G and H groups were increased compared to E and F groups. In tissue sections with arrow marks, the arrow a indicated the cortical staining area and the arrow b indicated the outer medulla stained area. Renal sections of all groups were observed to be positively stained for CYP4A in interlobar, arcuate and interlobular arteries. However, no positive enhancement was observed in the sections. (B): Under the normal diet, renal CYP2J2 expression was significantly elevated in CYP2C11-null females compared with WT females (P < 0.01, n = 5). We observed the same between-strain difference under the high-salt diet, except in both sexes (P < 0.01, n = 5). No significant difference was found for CYP4A expression. Density (mean) = integrated optical density (IOD)/Area. All data were expressed as means ± standard deviation. **P < 0.01.
**A**

![Image showing tissue sections labeled A to P, with annotations indicating normal and high-salt diets for CYP2J2 and CYP4A.]

**B**

![Box plots showing mean density of CYP2J2 and CYP4A in normal and high-salt diets for WT-M, WT-F, CYP2C11-null-M, and CYP2C11-null-F.](chart.png)

- WT-M
- WT-F
- CYP2C11-null-M
- CYP2C11-null-F
Table 1 (on next page)

Sequences of the real-time PCR primers.
Table 1. Sequences of the real-time PCR primers.

| Gene  | Primer Sequence                      |
|-------|-------------------------------------|
| CYP2C23 | 5’- GGCTGTCTGTGGGTCTAACT -3’          |
|        | 5’- AGGCAGCTTCATCTTGTCTT -3’         |
| CYP2C24 | 5’- AGGCTGTGATGGATGATCCAGTCA -3’     |
|        | 5’- AGGCTTCGGACAAAAGTACA -3’         |
| CYP2J2  | 5’- TTCCTACTCTCTGGCTGAC -3’          |
|        | 5’- TTTATTGGGTATGCGTTC -3’           |
| CYP4A1  | 5’- GCAGTGTTCAGGTGGAT -3’            |
|        | 5’- CTGGCAAGTAAGAGGATG -3’           |
| β-actin | 5’- TGGGAATCCTCTGTGGCATCCATGAAAC-3’  |
|        | 5’- TAAAACGCAGCTCAGTAACAGTCG-3’      |